Analogously, Nintedanib (Cyendiv, Boehringer-Ingelheim) 2 (Chart 1), a potent triple VEGFR, PDGFR, and FGFR angiokinase inhibitor, does not elicit beneficial effects in GBM, likely due to its limited CNS penetration. The gene discussed is PDGFRB; the disease is glioblastoma.